Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology
Bristow RG, Alexander B, Baumann M, Bratman SV, Brown JM, Camphausen K, Choyke P, Citrin D, Contessa JN, Dicker A, Kirsch DG, Krause M, Le QT, Milosevic M, Morris ZS, Sarkaria JN, Sondel PM, Tran PT, Wilson GD, Willers H, Wong RKS, Harari PM. Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology. The Lancet Oncology 2018, 19: e240-e251. PMID: 29726389, DOI: 10.1016/s1470-2045(18)30096-2.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsChemoradiotherapyConsensusGene Expression Regulation, NeoplasticHumansImmunologic FactorsImmunotherapyMolecular Targeted TherapyNeoplasmsPrecision MedicineRadiation OncologyRadiation ToleranceTreatment OutcomeConceptsMolecular targetingLocal tumor controlRadiation oncologyRadiation Oncology guidelinesSelection of therapyExternal beam radiotherapyRadiosensitivity of tumorsCancer survival outcomesPrecision radiotherapyAmerican SocietyRadiation dose prescriptionImmunotherapy agentsAberrant cell signalingImmunomodulatory agentsSurvival outcomesOncology guidelinesTumor controlImage-guided external beam radiotherapyPrecision cancer medicineBeam radiotherapyDose prescriptionSolid tumorsRadiotherapyTumor microenvironmentGenetic susceptibility